NASDAQ:PDLI - PDL BioPharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.37 -0.05 (-2.07 %)
(As of 06/24/2018 09:10 AM ET)
Previous Close$2.37
Today's Range$2.36 - $2.51
52-Week Range$2.15 - $3.55
Volume2.48 million shs
Average Volume2.10 million shs
Market Capitalization$364.55 million
P/E Ratio3.72
Dividend YieldN/A
PDL BioPharma logoPDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of notes and other long-term receivables; royalty rights and hybrid notes/royalty receivables; equity investments in healthcare companies; and royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The Medical Devices segment manufactures and sells LENSAR laser systems for anterior capsulotomy, lens fragmentation, corneal and arcuate incisions to ophthalmic ambulatory surgical centers, specialty ophthalmic hospitals, and multi-specialty hospitals through a direct sales force. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity Ratio0.14
Current Ratio10.03
Quick Ratio9.75


Trailing P/E Ratio3.72
Forward P/E Ratio10.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$320.06 million
Price / Sales1.12
Cash Flow$0.8618 per share
Price / Cash2.75
Book Value$5.48 per share
Price / Book0.43


EPS (Most Recent Fiscal Year)$0.63
Net Income$110.74 million
Net Margins33.57%
Return on Equity11.76%
Return on Assets8.04%


Outstanding Shares150,640,000

The Truth About Cryptocurrencies

PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its Board of Directors has authorized a share repurchase plan on Monday, September 25th 2017, which authorizes the company to repurchase $25,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its shares are undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) announced its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.02. The biotechnology company had revenue of $38.52 million for the quarter. PDL BioPharma had a net margin of 33.57% and a return on equity of 11.76%. View PDL BioPharma's Earnings History.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for PDL BioPharma.

What price target have analysts set for PDLI?

2 analysts have issued 12-month target prices for PDL BioPharma's stock. Their forecasts range from $2.50 to $4.00. On average, they anticipate PDL BioPharma's share price to reach $3.25 in the next year. View Analyst Ratings for PDL BioPharma.

Who are some of PDL BioPharma's key competitors?

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:
  • Mr. John Peter McLaughlin J.D., CEO & Director (Age 66)
  • Mr. Peter S. Garcia, VP & CFO (Age 56)
  • Mr. Steffen Pietzke, VP of Fin. & Chief Accounting Officer (Age 46)
  • Mr. Christopher L. Stone J.D., VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Dominique P. Monnet, Pres (Age 57)

Has PDL BioPharma been receiving favorable news coverage?

Headlines about PDLI stock have trended somewhat negative recently, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PDL BioPharma earned a daily sentiment score of -0.02 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 44.81 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.62%), Dimensional Fund Advisors LP (7.60%), Northern Trust Corp (3.28%), Schwab Charles Investment Management Inc. (2.26%), Royal Bank of Canada (1.84%) and Kestrel Investment Management Corp (1.08%). View Institutional Ownership Trends for PDL BioPharma.

Which major investors are selling PDL BioPharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Seizert Capital Partners LLC, JPMorgan Chase & Co., California Public Employees Retirement System, Prudential Financial Inc., Federated Investors Inc. PA, Citigroup Inc. and BlackRock Inc.. View Insider Buying and Selling for PDL BioPharma.

Which major investors are buying PDL BioPharma stock?

PDLI stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp, Dimensional Fund Advisors LP, Matarin Capital Management LLC, Schwab Charles Investment Management Inc., SG Americas Securities LLC, Mackay Shields LLC, Element Capital Management LLC and UBS Group AG. View Insider Buying and Selling for PDL BioPharma.

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $2.37.

How big of a company is PDL BioPharma?

PDL BioPharma has a market capitalization of $364.55 million and generates $320.06 million in revenue each year. The biotechnology company earns $110.74 million in net income (profit) each year or $0.63 on an earnings per share basis. PDL BioPharma employs 87 workers across the globe.

How can I contact PDL BioPharma?

PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]

MarketBeat Community Rating for PDL BioPharma (PDLI)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.